Palisade Capital

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for gastrointestinal (GI) diseases. The company's primary focus is its GID (Gastrointestinal Delivery) platform, which enables the targeted delivery of drugs directly to the GI tract to improve safety and efficacy. Its lead candidate, PALI-2108, is a colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug currently in Phase 1 development for ulcerative colitis. Additionally, the company is advancing LB1148, a protease inhibitor designed to reduce post-surgical adhesions and accelerate the return of bowel function. Palisade Bio aims to address significant unmet needs in inflammatory and post-operative GI care through its localized treatment approach.